Skip to main content
Premium Trial:

Request an Annual Quote

Cisbio to Offer BioTrove Screening Service

NEW YORK (GenomeWeb News) — Cisbio Bioassays will offer BioTrove's mass spectrometry screening service for assay development and drug screening to customers in the US, BioTrove said today.

Under the co-exclusive distribution agreement, Cisbio will offer BioTrove's RapidFire high-throughput service as a label-free detection method in conjunction with its Homogenous Time-Resolved Fluorescence, or HTRF technology and services. BioTrove will perform the RapidFire services at its screening facility.

HTRF is used for the detection of molecular interactions of proteins in vitro and is used for primary and secondary drug development screening.

Used together, the RapidFire and HTRF technologies will be used to study standard drug targets in the lead discovery phase and around 20 percent of drug targets that are difficult to study using fluorescent or radiolabel screening, BioTrove said.

"Cisbio's expertise in HTRF technology and significant sales presence among biopharma clients, combined with BioTrove's unique mass-spectrometry technology, will now provide customers access to a single, comprehensive source for drug discovery screening analysis," BioTrove President and CEO Al Luderer said in a statement.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.